Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis
- 11 January 2008
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 216 (3), 260-270
- https://doi.org/10.1159/000113150
Abstract
Health-related quality of life (HRQOL) outcomes are associated with clinical response to treatment in psoriasis. However, the association between HRQOL outcomes and more substantial degrees of Psoriasis Area and Severity Index (PASI) response and physician and patient global ratings remains ill defined. This study examined the relationship between achieving a 75% or > or =90% improvement in PASI and HRQOL outcome measures. Secondary analyses were completed using data for 1,469 patients with moderate to severe plaque psoriasis from two adalimumab clinical trials. HRQOL was measured via the Dermatology Life Quality Index (DLQI) and the Short Form 36 (SF 36) Health Survey. Clinical response was assessed by the PASI, physician's global assessment and patient's global assessment status scores. Clinical response was categorized into 6 groups based on PASI response: 10-point decrease in DLQI total scores. Moreover, these changes were statistically significantly greater than those observed for the PASI 75 to 4 points in the Mental Component and Physical Component Summary (MCS and PCS) scores. Statistically significantly greater differences in DLQI total and SF 36 summary and scale scores were also observed between patient's global assessment categories (p < 0.0001) and between physician's global assessment categories (p < 0.0001). Improvement in PASI response of >75% corresponded to improvements in HRQOL outcome measures for patients with moderate to severe psoriasis. PASI 90 or 100 responders had greater improvements in DLQI total score than PASI 75 responders.Keywords
This publication has 31 references indexed in Scilit:
- Role of Depression in Quality of Life for Patients with PsoriasisDermatology, 2007
- Adalimumab treatment is associated with improvement in health‐related quality of life in psoriasis: Patient‐reported outcomes from a Phase II randomized controlled trialJournal of Dermatological Treatment, 2007
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension studyJournal of the American Academy of Dermatology, 2006
- Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trialBritish Journal of Dermatology, 2005
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- Biological therapies in the systemic management of psoriasis: International Consensus ConferenceBritish Journal of Dermatology, 2004
- AAD consensus statement on psoriasis therapiesJournal of the American Academy of Dermatology, 2003
- Intramuscular Alefacept Improves Health-Related Quality of Life in Patients with Chronic Plaque PsoriasisDermatology, 2003
- The impact of psoriasis on quality of lifeBritish Journal of Dermatology, 2001
- Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQIBritish Journal of Dermatology, 1999